New Tool Predicts Prostate Cancer Patients' Response to LuPSMA Therapy
A new tool has been developed to predict which men with advanced metastatic prostate cancer will respond well to a novel targeted therapy called LuPSMA. The tool, published in Lancet Oncology, combines clinical and imaging data to stratify patients into high-risk and low-risk groups based on predicted survival.
LuPSMA, currently pending FDA approval, works by binding to PSMA proteins and delivering targeted radiation to prostate cancer tissue. The new prognostic tool, developed by a team led by Dr. Axel Bex, uses a nomogram that considers eight parameters to create a mathematical formula predicting survival in response to LuPSMA. This tool was created using data from 270 prostate cancer patients who underwent LuPSMA treatment.
The nomogram helps identify low-risk men who have longer overall survival (24 months) and progression-free survival (6 months) compared to high-risk men (6 months and 2 months, respectively). It also aids in screening candidates for LuPSMA therapy using PSMA PET imaging to detect prostate cancer and verify PSMA-expression in tumors. The tool demonstrates that a combination of clinical characteristics and PSMA PET imaging characteristics can predict patient response to LuPSMA treatment.
The new prognostic tool offers hope for better patient selection and improved outcomes in advanced metastatic prostate cancer treatment with LuPSMA. It provides a more personalized approach to care, helping to identify those most likely to benefit from this targeted therapy.
